List of articles with "Akeso"

Akeso's Alzheimer's Breakthrough

2025-11-17 02:40:24

China Hong Kong Alzheimer's Akeso AK152

Akeso's IL-1RAP Antibody

2025-11-07 16:43:15

Hong Kong Akeso National Harbor, Maryland SITC AK135

Ivonescimab Study Results

2025-11-07 16:42:27

China Hong Kong Akeso Ivonescimab HARMONi-A

Ivonescimab's Breakthrough

2025-11-03 04:21:31

China Hong Kong TNBC Akeso Ivonescimab

Immunotherapy Breakthrough

2025-10-30 15:15:55

Hong Kong Akeso Ivonescimab HARMONi-A

Cadonilimab in Cancer Care

2025-10-19 15:44:18

Hong Kong gastric cancer Akeso Cadonilimab

Ivonescimab ESMO 2025

2025-10-16 04:31:33

China Hong Kong oncology Akeso Ivonescimab

Akeso's Cancer Breakthrough

2025-09-22 07:02:20

Hong Kong Cancer Research Akeso AK130

Ligufalimab Receives ODD

2025-09-16 02:33:10

AML Akeso Ligufalimab

Akeso Trials Begin

2025-09-15 04:21:25

None Akeso Cadonilimab HCC

Lung Cancer Breakthrough

2025-09-10 02:52:39

Hong Kong Akeso Cadonilimab Pulocimab

Akeso Completes Enrollment

2025-09-02 08:13:36

China Hong Kong Akeso Ivonescimab biliary tract cancer

Akeso 2025 Interim Highlights

2025-08-26 16:23:20

Akeso Cadonilimab Ivonescimab

Akeso's Phase 3 Success

2025-08-25 05:51:19

Hong Kong Akeso Gumokimab Manfidokimab

Cadonilimab Trial

2025-08-20 08:23:22

China Hong Kong Akeso Cadonilimab G/GEJ Adenocarcinoma

Akeso IVONES Trial

2025-08-11 02:56:38

Hong Kong Akeso Ivonescimab SCLC

Akeso Cadonilimab Trial

2025-08-04 06:09:10

Hong Kong liver cancer Akeso Cadonilimab

Akeso's NSCLC Study Progress

2025-07-31 02:06:16

Hong Kong Akeso Ivonescimab NSCLC

Ivonescimab Approved

2025-07-28 04:22:18

China Hong Kong Cancer Treatment Akeso Ivonescimab

Ivonescimab Trial Launch

2025-07-24 01:22:19

Hong Kong pancreatic cancer Akeso Ivonescimab

Akeso's Ivonescimab Trial

2025-07-16 02:03:41

Hong Kong Akeso Ivonescimab Colorectal Cancer

Akeso's First Bispecific ADC

2025-07-03 06:57:21

Hong Kong Akeso TROP2 Nectin4

Cadonilimab at ASCO 2025

2025-06-16 01:29:22

None Akeso Cadonilimab Cervical Cancer

Cadonilimab Approved

2025-06-05 01:43:20

China Hong Kong Akeso Cadonilimab Cervical Cancer

Akeso's Penpulimab Approval

2025-05-14 21:33:18

USA Las Vegas Akeso Penpulimab nasopharyngeal carcinoma

Ivonescimab Approval

2025-04-25 17:33:33

China Hong Kong Akeso Ivonescimab NSCLC

FDA Approves Penpulimab-kcqx

2025-04-25 00:18:30

FDA Approval Hong Kong Akeso Penpulimab-kcqx

Ivonescimab Lung Cancer Breakthrough

2025-04-23 00:28:37

China Shanghai Akeso Ivonescimab Lung Cancer

Ebdarokimab Approved

2025-04-18 11:45:49

China Hong Kong Akeso Psoriasis Ebdarokimab

Akeso's 2024 Innovations

2025-03-30 18:41:22

Hong Kong Akeso Cadonilimab Ivonescimab

Penpulimab Approval

2025-03-17 04:00:24

China Hong Kong Akeso Penpulimab NPC

Akeso Clinical Trial Results

2025-03-07 05:08:23

Hong Kong Akeso Ivonescimab Pembrolizumab

Akeso Cadonilimab Update

2025-03-06 00:32:19

China Hong Kong Akeso Cadonilimab HCC

Akeso Launches ADC Trial

2025-02-27 09:05:12

Australia ADC Akeso AK138D1

Akeso's New Treatment Trial

2025-02-21 00:58:29

Hong Kong TNBC Akeso Ivonescimab

Akeso's Innovative AK139

2025-02-14 01:14:26

Hong Kong Akeso bispecific antibody AK139

Akeso's Cadonilimab Trial

2025-02-13 01:35:42

China Hong Kong Akeso Cadonilimab NSCLC

Akeso's Trial Enrollment Complete

2025-02-06 01:30:24

Hong Kong Akeso Ivonescimab Tislelizumab

Gumokimab for Psoriasis

2025-01-27 02:00:21

China Hong Kong Akeso Psoriasis Gumokimab

Cadonilimab Phase III Insights

2025-01-23 00:39:53

Hong Kong gastric cancer Akeso Cadonilimab

Akeso Drug Development

2025-01-07 03:24:21

United States biopharmaceuticals San Francisco Drug Development Akeso

Cadonilimab Results Unveiled

2024-12-04 05:16:11

Hong Kong Akeso Cadonilimab NSCLC

Akeso's New Drug List Inclusion

2024-11-28 04:04:50

China Hong Kong Akeso Cadonilimab Ivonescimab